UNIGE document Scientific Article
previous document  unige:99033  next document
add to browser collection
Title

Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective
Authors
Von Dach, Elodie
Morel, C M
Murthy, A
Pagani, L
Macedo-Vinas, M
Olearo, Flaminia
Harbarth, Stéphan Juergen
Published in Clinical Microbiology and Infection. 2017, vol. 23, no. 9, p. 659-666
Abstract Few industry-independent studies have been conducted to compare the relative costs and benefits of drugs to treat methicillin-resistant Staphylococcus aureus (MRSA) infection. We performed a stochastic cost-effectiveness analysis comparing two treatment strategies-linezolid versus trimethoprim-sulfamethoxazole plus rifampicin-for the treatment of MRSA infection.
Identifiers
PMID: 28232163
Full text
Article (Published version) (1.5 MB) - public document Free access
Structures
Faculté de médecine / Section de médecine clinique / Département de médecine
Research group Groupe Harbarth Stephan (Staphylocoques dorés résistants à la méthicilline) (866)
Citation
(ISO format) 		VON DACH, Elodie et al. Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective. In: Clinical Microbiology and Infection, 2017, vol. 23, n° 9, p. 659-666. doi: 10.1016/j.cmi.2017.02.011 https://archive-ouverte.unige.ch/unige:99033

320 hits

179 downloads

Contact an author

Update request

Update

Deposited on : 2017-11-15

Export document
Format :
Citation style :